It has been described that TCR-activated Cd38−/− CD4+ T cells show a hybrid Th1/Th17 phenotype exhibiting intrinsically higher NAD+, enhanced oxidative phosphorylation, higher glutaminolysis, and altered mitochondrial dynamics that vastly improved tumor control (54, 55). Here, CD38 is linked to neoplasm.